Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Veracyte (VCYT) Other Accumulated Expenses: 2012-2025

Historic Other Accumulated Expenses for Veracyte (VCYT) over the last 5 years, with Mar 2025 value amounting to $7,000.

  • Veracyte's Other Accumulated Expenses fell 92.13% to $7,000 in Q1 2025 from the same period last year, while for Mar 2025 it was $7,000, marking a year-over-year decrease of 92.13%. This contributed to the annual value of $19,000 for FY2024, which is 81.19% down from last year.
  • Veracyte's Other Accumulated Expenses amounted to $7,000 in Q1 2025, which was down 63.16% from $19,000 recorded in Q4 2024.
  • Over the past 5 years, Veracyte's Other Accumulated Expenses peaked at $241,000 during Q3 2021, and registered a low of $7,000 during Q1 2025.
  • Moreover, its 3-year median value for Other Accumulated Expenses was $89,000 (2024), whereas its average is $77,000.
  • Data for Veracyte's Other Accumulated Expenses shows a maximum YoY tumbled of 92.13% (in 2025) over the last 5 years.
  • Veracyte's Other Accumulated Expenses (Quarterly) stood at $231,000 in 2021, then dropped by 19.48% to $186,000 in 2022, then crashed by 45.70% to $101,000 in 2023, then slumped by 81.19% to $19,000 in 2024, then slumped by 92.13% to $7,000 in 2025.
  • Its Other Accumulated Expenses was $7,000 in Q1 2025, compared to $19,000 in Q4 2024 and $53,000 in Q3 2024.